Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss
NCT05237843Phase 1Unknown
- Sponsor
- Ain Shams University
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of hydroxychloroquine in recurrent pregnancy loss (RPL), sponsored by Ain Shams University. Primary endpoint: Change rate of pregnancy loss at 1 year. Status: unknown.
02
Drugs
hydroxychloroquine
03
Conditions
recurrent pregnancy loss (RPL)
Beyond the preview
Go deeper on NCT05237843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05237843.